15+ Years at Wyss Institute at Harvard University      |      10+ Years in Pharmaceutical Development Industry

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Breaking down cancer cells to build a better vaccine? 🧫🧬 We previously found a clever way to improve personalized cancer immunotherapies. Traditionally, scientists use "tumor lysate" (broken down cancer cells) to teach the immune system what to fight. The problem? Lysate doesn't always trigger a strong immune response. Enter "Reduced Cancer Cells" (RCCs). In this study, we mechani

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Our recently published article entitled "Kinetics of De Novo Bone and Bone Marrow Niche Formation With Hybrid Click Cryogels", explores strategies to rebuild the bone marrow environment to improve the success of hematopoietic stem cell transplantation (HSCT). Full report @ https://is.gd/1tleYm Main Objective The study addresses the problem of damaged bone marrow niches following irr